Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Avutometinib and defactinib |
| Synonyms | |
| Therapy Description |
Avmapki Fakzynja Co-pack (avutometinib and defactinib) is a combination drug that consists of the RAF/MEK inhibitor Avutometinib and the FAK inhibitor Defactinib, which may synergistically inhibit tumor growth (PMID: 39240189). Avmapki Fakzynja Co-pack (avutometinib and defactinib) is FDA-approved for use in patients with KRAS-mutant recurrent low-grade serous ovarian cancer (FDA.gov). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Avutometinib and defactinib | Avmapki Fakzynja Co-pack | FAK inhibitor 16 MEK inhibitor (Pan) 27 MEK1 Inhibitor 27 MEK2 Inhibitor 25 RAF Inhibitor (Pan) 29 | Avmapki Fakzynja Co-pack (avutometinib and defactinib) is a combination drug that consists of the RAF/MEK inhibitor Avutometinib and the FAK inhibitor Defactinib, which may synergistically inhibit tumor growth (PMID: 39240189). Avmapki Fakzynja Co-pack (avutometinib and defactinib) is FDA-approved for use in patients with KRAS-mutant recurrent low-grade serous ovarian cancer (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|